Exosome Diagnostics is a leader in developing liquid biopsy-based diagnostics. It’s exosome-based diagnostic, a rule-out test for prostate biopsy, is now recommended by the National Comprehensive Cancer Network, available through urologists. Exosome Diagnostics is the first and only company that can simultaneously isolate and analyze exosomal RNA and cfDNA in a single step to achieve highest sensitivity for detecting rare mutations. Exosome Diagnostics empowers the world’s leading biopharma company’s biomarker discovery, translational research, and clinical trials through partnerships.